Meaning-Centered Psychotherapy in Advanced Cancer

This study has been completed.
Sponsor:
Information provided by:
National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier:
NCT00067288
First received: August 14, 2003
Last updated: August 16, 2006
Last verified: August 2006
  Purpose

We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.


Condition Intervention Phase
Lymphoma, Non-Hodgkin
Neoplasms
Behavioral: Meaning-Centered Group Psychotherapy
Behavioral: Standard Supportive Group Psychotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
Official Title: Meaning-Centered Psychotherapy in Advanced Cancer

Resource links provided by NLM:


Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment: 118
Study Start Date: May 2002
Estimated Study Completion Date: March 2006
Detailed Description:

As per Brief Summary

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 21 years of age or older;
  • English speaking;
  • Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma;
  • Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City;

Exclusion Criteria:

  • Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention;
  • Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent;
  • Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067288

Locations
United States, New York
Memorial Sloan-Kettering Institute for Cancer Research
New York, New York, United States, 10021
Sponsors and Collaborators
Investigators
Principal Investigator: William Breitbart, MD Memorial Sloan-Kettering Cancer Center
Investigator: Christopher Gibson, PhD Project Coordinator Memorial Sloan-Kettering Cancer Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00067288     History of Changes
Other Study ID Numbers: R21 AT001031-01, Breitbart
Study First Received: August 14, 2003
Last Updated: August 16, 2006
Health Authority: United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
Stage 3 cancer;
Stage 4 cancer;
solid tumor cancer;
Non-Hodgkin's Lymphoma;
solid tumors;
end-stage cancer;
group psychotherapy;
psychotherapy;
emotional support;
support groups

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on September 18, 2014